{"name":"BioNTech SE","slug":"biontech-se","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"immunology","drugs":[{"name":"Influenza","genericName":"Influenza and COVID-19 Combination B","slug":"influenza-and-covid-19-combination-b","indication":"aches","status":"marketed"},{"name":"Influenza","genericName":"Influenza and COVID-19 Combination A","slug":"influenza-and-covid-19-combination-a","indication":"Symptoms of colds and flu","status":"marketed"},{"name":"Investigational Influenza Vaccine","genericName":"Investigational Influenza Vaccine","slug":"investigational-influenza-vaccine","indication":"Other","status":"phase_3"},{"name":"Licensed COVID-19 Vaccine","genericName":"Licensed COVID-19 Vaccine","slug":"licensed-covid-19-vaccine","indication":"Other","status":"phase_1"},{"name":"Licensed Influenza Vaccine 1","genericName":"Licensed Influenza Vaccine 1","slug":"licensed-influenza-vaccine-1","indication":"Other","status":"phase_1"},{"name":"Licensed Influenza Vaccine 2","genericName":"Licensed Influenza Vaccine 2","slug":"licensed-influenza-vaccine-2","indication":"Influenza prevention","status":"marketed"},{"name":"BNT152","genericName":"BNT152","slug":"bnt152","indication":"Other","status":"phase_1"},{"name":"BNT162b2SA","genericName":"BNT162b2SA","slug":"bnt162b2sa","indication":"Other","status":"phase_2"},{"name":"BNT162b2s01","genericName":"BNT162b2s01","slug":"bnt162b2s01","indication":"Other","status":"phase_2"},{"name":"Pumitamig","genericName":"Pumitamig","slug":"pumitamig","indication":"Other","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"cardiovascular","drugs":[{"name":"Investigational COVID-19 Vaccine","genericName":"Investigational COVID-19 Vaccine","slug":"investigational-covid-19-vaccine","indication":"Prevention of COVID-19 in individuals 5 years of age and older","status":"marketed"},{"name":"BNT111","genericName":"BNT111","slug":"bnt111","indication":"COVID-19 prevention","status":"phase_2"},{"name":"BNT162b1","genericName":"BNT162b1","slug":"bnt162b1","indication":"COVID-19 prevention","status":"phase_2"},{"name":"BNT162b2.B.1.351","genericName":"BNT162b2.B.1.351","slug":"bnt162b2-b-1-351","indication":"COVID-19 prevention (variant-specific booster or primary series against B.1.351 variant)","status":"phase_3"},{"name":"BNT324","genericName":"BNT324","slug":"bnt324","indication":"Prevention of respiratory syncytial virus (RSV) infection in adults aged 60 years and older","status":"phase_3"},{"name":"BNT327 Equivalent Q3W Dose","genericName":"BNT327 Equivalent Q3W Dose","slug":"bnt327-equivalent-q3w-dose","indication":"COVID-19 prevention","status":"phase_2"},{"name":"BNT327 Optimized Dose","genericName":"BNT327 Optimized Dose","slug":"bnt327-optimized-dose","indication":"Prevention of COVID-19","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"neuroscience","drugs":[{"name":"BNT166a","genericName":"BNT166a","slug":"bnt166a","indication":"Melanoma (in combination with Merck's Keytruda/pembrolizumab)","status":"phase_2"},{"name":"BNT323/DB-1303","genericName":"BNT323/DB-1303","slug":"bnt323-db-1303","indication":"Solid tumors (specific indication under clinical evaluation in Phase 3)","status":"phase_3"},{"name":"Nab-paclitaxel/Paclitaxel","genericName":"Nab-paclitaxel/Paclitaxel","slug":"nab-paclitaxel-paclitaxel","indication":"Metastatic breast cancer","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Assorted Licensed Hand Sanitizer Grape 01","genericName":"Licensed Influenza Vaccine 3","slug":"licensed-influenza-vaccine-3","indication":"Intranasal influenza vaccine for active immunization against influenza disease caused by influenza virus types A and B, in individuals 6 years of age and older","status":"marketed"}]}],"pipeline":[{"name":"Assorted Licensed Hand Sanitizer Grape 01","genericName":"Licensed Influenza Vaccine 3","slug":"licensed-influenza-vaccine-3","phase":"marketed","mechanism":"Influenza virus hemagglutinin protein","indications":["Intranasal influenza vaccine for active immunization against influenza disease caused by influenza virus types A and B, in individuals 6 years of age and older"],"catalyst":""},{"name":"Influenza","genericName":"Influenza and COVID-19 Combination B","slug":"influenza-and-covid-19-combination-b","phase":"marketed","mechanism":"Not specified","indications":["aches","cold symptoms","cramping","discomfort","fatigue"],"catalyst":""},{"name":"Influenza","genericName":"Influenza and COVID-19 Combination A","slug":"influenza-and-covid-19-combination-a","phase":"marketed","mechanism":"SARS-CoV-2 spike protein and influenza hemagglutinin protein","indications":["Symptoms of colds and flu"],"catalyst":""},{"name":"Investigational COVID-19 Vaccine","genericName":"Investigational COVID-19 Vaccine","slug":"investigational-covid-19-vaccine","phase":"marketed","mechanism":"Not specified","indications":["Prevention of COVID-19 in individuals 5 years of age and older","Prevention of COVID-19 in individuals 6 months through 4 years of age","Prevention of COVID-19 in individuals 12 years of age and older","Prevention of COVID-19 in individuals 6 months through 4 years of age with certain health conditions","Prevention of COVID-19 in individuals 5 years of age and older with certain health conditions"],"catalyst":""},{"name":"Investigational Influenza Vaccine","genericName":"Investigational Influenza Vaccine","slug":"investigational-influenza-vaccine","phase":"phase_3","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Licensed COVID-19 Vaccine","genericName":"Licensed COVID-19 Vaccine","slug":"licensed-covid-19-vaccine","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Licensed Influenza Vaccine 1","genericName":"Licensed Influenza Vaccine 1","slug":"licensed-influenza-vaccine-1","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Licensed Influenza Vaccine 2","genericName":"Licensed Influenza Vaccine 2","slug":"licensed-influenza-vaccine-2","phase":"marketed","mechanism":"Not specified","indications":["Influenza prevention","Influenza protection","Influenza prevention for adults and children 6 years and older"],"catalyst":""},{"name":"BNT166a","genericName":"BNT166a","slug":"bnt166a","phase":"phase_2","mechanism":"BNT166a is an mRNA vaccine designed to encode tumor-associated antigens and stimulate anti-tumor immune responses.","indications":["Melanoma (in combination with Merck's Keytruda/pembrolizumab)","Colorectal cancer (in development)"],"catalyst":""},{"name":"BNT111","genericName":"BNT111","slug":"bnt111","phase":"phase_2","mechanism":"BNT111 is a COVID-19 vaccine candidate.","indications":["COVID-19 prevention"],"catalyst":""},{"name":"BNT152","genericName":"BNT152","slug":"bnt152","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BNT162b1","genericName":"BNT162b1","slug":"bnt162b1","phase":"phase_2","mechanism":"mRNA-based vaccine","indications":["COVID-19 prevention"],"catalyst":""},{"name":"BNT162b2.B.1.351","genericName":"BNT162b2.B.1.351","slug":"bnt162b2-b-1-351","phase":"phase_3","mechanism":"BNT162b2.B.1.351 is an mRNA vaccine encoding a modified spike protein from the B.1.351 (Beta) variant of SARS-CoV-2, designed to elicit immune responses against this variant.","indications":["COVID-19 prevention (variant-specific booster or primary series against B.1.351 variant)"],"catalyst":""},{"name":"BNT162b2SA","genericName":"BNT162b2SA","slug":"bnt162b2sa","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"BNT162b2s01","genericName":"BNT162b2s01","slug":"bnt162b2s01","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"BNT323/DB-1303","genericName":"BNT323/DB-1303","slug":"bnt323-db-1303","phase":"phase_3","mechanism":"BNT323/DB-1303 is a bispecific antibody that simultaneously engages tumor-associated antigens and immune effector cells to redirect immune responses against cancer cells.","indications":["Solid tumors (specific indication under clinical evaluation in Phase 3)"],"catalyst":""},{"name":"BNT324","genericName":"BNT324","slug":"bnt324","phase":"phase_3","mechanism":"BNT324 is an mRNA vaccine designed to elicit an immune response against RSV (respiratory syncytial virus) by encoding viral antigens.","indications":["Prevention of respiratory syncytial virus (RSV) infection in adults aged 60 years and older","Prevention of RSV disease in older adults"],"catalyst":""},{"name":"BNT327 Equivalent Q3W Dose","genericName":"BNT327 Equivalent Q3W Dose","slug":"bnt327-equivalent-q3w-dose","phase":"phase_2","mechanism":"BNT327 is a COVID-19 vaccine candidate that uses a modified mRNA molecule to instruct cells to produce a piece of the SARS-CoQV-2 virus, eliciting an immune response.","indications":["COVID-19 prevention"],"catalyst":""},{"name":"BNT327 Optimized Dose","genericName":"BNT327 Optimized Dose","slug":"bnt327-optimized-dose","phase":"phase_2","mechanism":"BNT327 is a mRNA-based vaccine that encodes for the SARS-CoV-2 spike protein.","indications":["Prevention of COVID-19"],"catalyst":""},{"name":"Nab-paclitaxel/Paclitaxel","genericName":"Nab-paclitaxel/Paclitaxel","slug":"nab-paclitaxel-paclitaxel","phase":"phase_3","mechanism":"Nab-paclitaxel is an albumin-bound formulation of paclitaxel that stabilizes microtubules to prevent cell division, inducing apoptosis in cancer cells.","indications":["Metastatic breast cancer","Non-small cell lung cancer","Pancreatic cancer","Ovarian cancer"],"catalyst":""},{"name":"Pumitamig","genericName":"Pumitamig","slug":"pumitamig","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQWmNzUkMzcEpEMnNjWnZvNE9xTDgyX0lSbWFOblJOaVRkb0k3QmFTelJuYmo2Q205RkNoa2RyMWpHX3ZnZXNNbGJxSzF6amI4b3JqQnU2ZVhrZGVFdkMxNlBuS0IxVkNzZWFkZGJWOTFVdUdScE05WWoxeFVRSHctUEJxc280U1MweXU2LW9aUVp6dlFCZEtXbVFocDJ1US15dE5oeHltOVhLNXJBS2c?oc=5","date":"2026-04-01","type":"pipeline","source":"straitstimes.com","summary":"BioNTech to close Singapore vaccine plant in early 2027 - straitstimes.com","headline":"BioNTech to close Singapore vaccine plant in early 2027","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNR1RSbmdma2Z6NGJydEc0cFUzejZiX3lGZzhWZmNuNGNJM2cwQlJpSXlzQlAzejZmVnFSTzRla3NoVkMtN04zQ0NjUk1uTHlfTFJSMG8zbkRTQjY2eVNCUXgwRXZIUVFpOGxHZjhXMFJHaXNEMk1ZeTAtTF8wcmg2TlQ3czVNdDRjRnRUbXdoTmlYRmVBODM0aVZ6aE1SV21nSTBaRTNpVXFSQms?oc=5","date":"2026-03-16","type":"pipeline","source":"The Motley Fool","summary":"Best Vaccine Stocks of 2026: Are They Right for Your Portfolio? - The Motley Fool","headline":"Best Vaccine Stocks of 2026: Are They Right for Your Portfolio?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPaWt0T0R2cW1sU0JaTEhzcjlLbU4xaldyQ01QakNUWmMwam1lUlQwQWNqNjd3VXVySVhVa0NwOTBLUi1sV0RqWld2Ql9ZeUZ4aFV1LThzQjc3RVVlUzEwV3h2Z2xfNEN5cFBlTHo0T0hHUEUwTUNpMG5PcWhuNFBONmFkMXRyOEszSE5JOUdTdzkwdjQ0WGVhYzdPSQ?oc=5","date":"2026-03-12","type":"pipeline","source":"news.financial","summary":"Breaking News! Takeover speculation? BioNTech, Evotec, Vidac Pharma - news.financial","headline":"Breaking News! Takeover speculation? BioNTech, Evotec, Vidac Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPRF92ZHBoZHMwUFRHZ1hDZEd4Nlh0RXFPMHN3MHFnNDM3MHRjYlloRnZPWllUV2NUYWxrV083TVpyVWhHT1l0MlpWWTZuYmhaY3BmZHl0SDg4UWZWS0RqTWZGOXh1VlVhN0dzRkptQ0ZFb1BuSDc4bVdPWGlWVXhVeHIydVMzM2VS?oc=5","date":"2026-02-26","type":"pipeline","source":"Pharmaceutical Technology","summary":"BioNTech mRNA Vaccine Manufacturing Facility, Rwanda - Pharmaceutical Technology","headline":"BioNTech mRNA Vaccine Manufacturing Facility, Rwanda","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQUzJDQTRnQ2pOU0JoUUJRT2YxYm9Qc3hIaFY4WktwR09HeDFLaVRCQ0dRRzF4RHJ1RnN3cTFVUFUyVzVjVFJjZmpuS3VCbTlpQ1RTQi1OcnhPWFZ1ZUJWTHpDN1hwbW51UGlBdUlFU3NrYzdXSWRob1Y0Q3F1QUs3c3dNcl9sNU16amtjT2lB?oc=5","date":"2026-02-05","type":"pipeline","source":"The Motley Fool","summary":"Best Biotech Stocks of 2026 and How to Invest in Them - The Motley Fool","headline":"Best Biotech Stocks of 2026 and How to Invest in Them","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE1iTEw4UmJiSHg0bFJFSmg4SkRtZ3VxczVsUTQxWHJsMmt5aUplUTNyaDVuLTdmbENFN0JxWnlCQkdPUG42UTdqcjBVRVo1SUEydElvRFN6Wjd4a2s1d1lzUjdzSGNIemlsU0FtX2d4Z0RUeGxB?oc=5","date":"2025-12-18","type":"pipeline","source":"CureVac","summary":"CureVac is now part of the BioNTech Group - CureVac","headline":"CureVac is now part of the BioNTech Group","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxQa05FSVl1VzgxRk5qSVlmV2NmLUNFclh1ZHowR1hYR1J3dUpqcmhJZjRxcldOU2ZuTk1vQlZ1X0NSV3pVMVgyU3pQSm50cm1ER0R0SlZpbVZndVpMdzQwWGV4aVE0TEpITVpJQWNtQmx0cXdtTDFaenN6QUJOOTZLaU9tczZCSmt5VXFoZEZmTTlsRlZaSG9VMzRoQW9nTlBvdTk0RFRKMHJWN3poYlNoWnRzaFUtQTZ3NjQ0TDVmTUd0ZVhRUWZlZGh2cTRBcXI0UVAxTlNSaEkyU19L?oc=5","date":"2025-11-13","type":"deal","source":"Reuters","summary":"Pfizer slashes stake in COVID vaccine partner BioNTech - Reuters","headline":"Pfizer slashes stake in COVID vaccine partner BioNTech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOMFYxanhRMGk1TUwzdUpTVUVnYl8xWERXaS1iSTNQOGZ0eVZfYzFzbU9EVElJWGJXYjFLbEIwSlFwTmY4b21RNEU5SGdaUVc1ZDB3eWh2ME9lLW85Um11SWI5S0owTl80N2RBUDdZRlBGRGgxNjYxN0tnOEdKMHNjWFZGN2NZa2ZxbjlSeGpGVW1YRkVicW90VUdTRi1hM0JkaFB3aWgxRHBqTXFzSUFsTGlrQ1pzajQ?oc=5","date":"2025-11-03","type":"earnings","source":"seekingalpha.com","summary":"BioNTech Q3 Earnings: Plenty Of Cash And Pipeline Potential, But Still A Hold (BNTX) - seekingalpha.com","headline":"BioNTech Q3 Earnings: Plenty Of Cash And Pipeline Potential, But Still A Hold (BNTX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOQldYNEJ5X2xYWFhJTTdaeVpfTmVMZVhsWEpPY1I4bDdqb3d6R25JaUVtRzBVQzU4TGVRQVZlSG5kUi1oR3F4MXNyemJLandMclhtU2J0VEY3STFUZERYVFJOLVRTOG52cHNwNURNWjdoWGZub21tUVEwVUlrRjRaNTYyUDA2cDhBdFd4dlMzX2huTWsxYk42ZHE3ZHdMQ3VYdGg5NFEtRzF6bG04NjlyMThJNVFUV2xPRnNtY0k0eU91SDBBd0V3?oc=5","date":"2025-06-18","type":"pipeline","source":"Fierce Pharma","summary":"BioNTech to wind down cell therapy manufacturing in Maryland, lay off 63 as it ends development of CAR-T drug in testicular cancer - Fierce Pharma","headline":"BioNTech to wind down cell therapy manufacturing in Maryland, lay off 63 as it ends development of CAR-T drug in testicu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOdGxPVmYtTEVPdUdnTTF1eFc1eHJReVJ4TmJMX3JrdEpJci1KNlBjamRoaHZNQzJtVjdaRnRHdkhWbnA0R3FhWFcxS2dSX0dNYVhXVzFFZ0ZHaXAtVk5GQ1hYNjRfYUJncVlueFRtLUZhMnZHNUI1bks2bWc3bmVnRlVnRWJIUTFzRV9IdGhUc21rc3YwcjVGQmhvM0I5UHhvcXhkTUh3dlM3bHQ5cUlDaw?oc=5","date":"2025-06-12","type":"pipeline","source":"Pharmaceutical Technology","summary":"BioNTech bolsters mRNA pipeline with $1.25bn CureVac acquisition - Pharmaceutical Technology","headline":"BioNTech bolsters mRNA pipeline with $1.25bn CureVac acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPMkR3Tjl3Y1lEUHpjS2hkZW1ueTNpay1FelA4Q19zLV94UFFDZ1ZVT2k5Y1FJa2JGbGNhZEc5SWdIZlpJd1BtVzNXcTNBcVJzMW94VThnV3F6S3VjeHZ0S2pralEySkxnanFhbjNRR3RWZWY0Sm15LTVVMVJVRm9HYV9DamszOXZJTDF0SHFlRDlEYjhyaHVoNUlQQVFrTkhnSUl1NllMVC1YS3gzQnRyaHVYLWZnQQ?oc=5","date":"2025-06-03","type":"deal","source":"Contract Pharma","summary":"BioNTech, BMS Partner to Develop & Commercialize BNT327 for Solid Tumors - Contract Pharma","headline":"BioNTech, BMS Partner to Develop & Commercialize BNT327 for Solid Tumors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOSjBNV3BUdWtKWUZUd29EWnJORWQzYVZqbzNBSUwzZHV2LVNaNFJsMThaYjBIbngzalFKWVAycnQzMVo1TVFTTWhEYXJMc25QU1BBa254Q2xzYW9VUmVnaXJLTk1kTFJGcW9WMk41QjV4eG5OM0lLZDhENW9oQmxDQmt2MFJwbEs0Zk5yQm02WUp3Z09XM0RyZnRB?oc=5","date":"2025-05-21","type":"pipeline","source":"European Pharmaceutical Review","summary":"BioNTech pledges major UK investment - European Pharmaceutical Review","headline":"BioNTech pledges major UK investment","sentiment":"neutral"}],"patents":[],"drugCount":21,"phaseCounts":{"marketed":5,"phase_3":6,"phase_1":3,"phase_2":7},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}